[Back to Contents Page]

 

Current Topics in Medicinal Chemistry, Volume 3, No. 8, 2003

 

Contents

 

Obesity: Potential Targets for Pharmacological Intervention

Guest Editor: David L. Musso

 

CCK1R Agonists: A Promising Target for the Pharmacological Treatment of Obesity Pp.837-854

Jerzy R. Szewczyk  and Chris Laudeman

[Abstract]

 

The Melanocortin System and its Role in Obesity and Cachexia Pp.855-883

Val S. Goodfellow and John Saunders

[Abstract]

 

5-HT_2C Receptor Agonists as Potential Drugs for the Treatment of Obesity Pp.885-897

Michael J. Bickerdike

[Abstract]

 

Nicotine, Body Weight and Potential Implications in the Treatment of Obesity Pp.899-919

Ming D. Li , Justin K. Kane and Ozlen Konu

[Abstract]

 

Ghrelin in Hypothalamic Regulation of Energy Balance Pp.921-927

Tamas L. Horvath , Sabrina Diano , Matthias Tschop

[Abstract]

Abstracts

 

[Back to top] CCK1R Agonists: A Promising Target for the Pharmacological Treatment of Obesity

Jerzy R. Szewczyk  and Chris Laudeman

 

Almost 30 years have passed since Gibbs, Young, and Smith demonstrated the ability of exogenously administered cholecystokinin (CCK) to inhibit food intake in rats. This observation was the beginning of very extensive studies into the role CCK plays in the regulation of food intake in mammals. CCK is a brain-gut peptide, which exists in multiple forms. CCK peptides exert their action on two distinct receptor subtypes: CCK-A (Alimentary) now called the CCK1R, mostly expressed peripherally; and CCK-B (Brain), renamed the CCK2R, which is primarily present in the brain. Through the use of subtypeselective agonists and antagonists for the CCK receptor, it was determined that the effect of CCK on feeding was dependent on agonist induced activation of peripheral CCK1 receptors. This discovery was followed by intense research with the goal of identifying small molecule agonists on the CCK1 receptor as potentially useful agents for the treatment of obesity. This review will attempt to summarize the results of this research.

 

[Back to top] The Melanocortin System and its Role in Obesity and Cachexia

Val S. Goodfellow and John Saunders

 

Melanocortin receptors (MC-R) activated by one of several peptides derived from the proopiomelanocortin (POMC) precursor have become leading contenders for a pivotal role in controlling food intake. Evidence has emerged over the last decade to implicate primarily the MC4-R and, to a lesser extent, MC3-R as the key sub-types involved and both are strategically located in those regions within the hypothalamus known to be associated with feeding. The receptors are within class A of the GPCR superfamily and the key electrostatic interaction with the positively charged peptide (Arg⁸) has been mapped to one or more Asp or Glu residues located on helices II and III of the seven helical bundle characteristic of this class of receptor. Sites for secondary interactions from which sub-type selectivity may be derived have also been located in the extracellular and helical domains. Unique amongst GPCRs is the presence of endogenous antagonist peptides, Agouti and Agouti-related peptide (AGRP), which confer an extra level of control on the system. Recently, several reports of potent and selective non-peptide ligands have been published and these are seen as prototypic molecules from which drugs may emerge to treat obesity (agonists) and cachexia (antagonists). The role played by the melanocortin system is the subject of this review and advances in our understanding of the structure of the endogenous ligand(s), nonpeptide, small molecule ligands and the receptors at which they interact will be discussed.

 

[Back to top] 5-HT_2C Receptor Agonists as Potential Drugs for the Treatment of Obesity

Michael J. Bickerdike

 

An association between the brain serotonin (5-HT) system and feeding has been postulated since the 1970’s but it has only been in recent years that the nature of 5- HT-mediated hypophagia has become well understood, and the receptor subtypes responsible for the effect better defined. The invention and utilisation of subtypeselective 5-HT receptor antagonists has demonstrated that the 5-HT_2C receptor is of paramount importance in this regard. Importantly, ethological studies of animal behaviour have shown that the hypophagia resulting from 5-HT_2C receptor activation is likely to be a consequence of increased satiety and this is in contrast to hypophagia following 5-HT_2A receptor activation. Furthermore, recent studies have also shown that 5-HT_2C receptor agonists not only reduce feeding when acutely administered to rats or mice, they can also reduce body weight without inducing tolerance when chronically to obese animals. These observations have led researchers to conclude that selective 5- HT_2C receptor agonists have the potential to be effective anti-obesity agents. Encouragingly, this suggestion is supported by both direct and indirect evidence from clinical studies. Indirect evidence stems from recent observations that the clinically effective anorectic agent d-fenfluramine exerts its hypophagic and weight-loss effects via 5-HT_2C receptor activation. More direct clinical evidence derives from the use of the prototypical 5-HT_2C receptor agonist m-chlorophenylpiperazine (mCPP), with which both acute hypophagia and body-weight loss have been observed. The current paper therefore reviews both the pre-clinical and clinical evidence supporting the use of 5-HT_2C receptor agonists for the treatment of obesity and assesses the developments that have been made in this regard to date.

 

[Back to top] Nicotine, Body Weight and Potential Implications in the Treatment of Obesity

Ming D. Li , Justin K. Kane and Ozlen Konu

 

Obesity is an epidemic problem in the U. S. and many other industrialized nations. Historically, the drugs used for the treatment of obesity generally targeted small molecule neurotransmitters. As research grows to decipher the underlying molecular mechanisms behind energy homeostasis, it is becoming evident that the modulating effects of neuropeptides also are critical in the regulation of appetite and metabolism. The search for drugs to modify these monoaminergic and peptidergic pathways may eventually prove successful in the treatment of obesity. While tobacco smoking has long been used as one strategy to maintain a lower body weight, especially in female smokers, its adverse associations with addiction and disease overshadow its potential use as an antiobesity agent. Potential pharmacological effects of nicotine could be better understood as the intricacies of the nicotinic acetylcholine receptor are revealed. The objective of this review is threefold: first is to provide an overview of the physiological effects of nicotine on body weight while focusing on the drugs that are available as antiobesity and smoking cessation agents. Second is to provide the present status of the nicotinic acetylcholine receptor as it relates to energy homeostasis and its potential as an effective treatment modality for obesity. Third is to present the current knowledge with respect to nicotine’s effects on energy homeostatic and reward related pathways at the molecular level. A better understanding of the regulatory mechanisms underlying the pharmacological effects of nicotine on body weight will provide insights in identification of potential targets for the development of appropriate medicines in the treatment of obesity.

 

[Back to top] Ghrelin in Hypothalamic Regulation of Energy Balance

Tamas L. Horvath , Sabrina Diano , Matthias Tschop

 

The novel peptide hormone ghrelin has recently been recognized as an important co-regulator of growth hormone secretion and energy homeostasis. The significance of ghrelin for obesity and cachexia as well as in the regulation of growth processes is the subject of ongoing basic research as well as clinical studies. It is our goal to emphasize the critical significance of the hypothalamic signaling modalities induced by ghrelin for a better understanding of how this novel hormone affects energy balance and metablism.